Compare BioNano Genomics Inc (BNGO) vs Payoneer Global Inc (PAYO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Payoneer Global Inc — how do they compare? BioNano Genomics Inc trades at $1.2 (market cap $13.66M), while Payoneer Global Inc trades at $7.1 (market cap $2.40B). The key difference: Payoneer Global Inc is far larger — about 175.7× BioNano Genomics Inc's market cap, and Payoneer Global Inc is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.
| BNGO | PAYO | |
|---|---|---|
Market Cap | $13.66M | $2.40B |
Sector | Health | Technology |
52-Week High | $4.92 | $7.17 |
52-Week Low | $1.06 | $4.27 |
Enterprise Value | $16.26M | $2.14B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.19, up 2.59% today, with bullish technical signals from moving averages. The company shows improving financials with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable. Recent earnings have consistently beaten expectations, and analyst sentiment is positive with 57% buy ratings. Key developments include debt retirement and scientific publications highlighting optical genome mapping adoption.
The outlook is cautiously optimistic given improving fundamentals and positive analyst coverage, but significant risks remain due to persistent losses and negative cash flow. Investment opportunity lies in the company's technology adoption growth, while primary risks include profitability challenges and competitive pressures in the genomics space.
Payoneer (PAYO) trades at $7.07, down 0.28% on the day, with a bullish technical signal from moving averages and an oversold RSI. Revenue grew to $821.16M in 2025, but net income fell to $73.19M, and Q2 2026 earnings missed estimates. The company is set to be acquired by Nuvei for $7.40 per share, pending shareholder approval, amid legal scrutiny over deal fairness.
The outlook is acquisition-driven, with upside limited to the $7.40 buyout price unless a higher bid emerges. Risks include integration challenges, earnings volatility, and legal disputes. Analysts maintain a buy consensus with an $8.20 target, suggesting potential gains if the deal proceeds smoothly, but caution is warranted due to recent profit margin compression.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Payoneer Global Inc
Payoneer Global Inc is the world's go-to partner for digital commerce, everywhere. The company started as a cross-border payments platform that empowers businesses, online sellers, and freelancers. The platform allows the users to get paid in multiple currencies, bill global clients, and sell on marketplaces worldwide.
Read more on PAYO →
